Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
At least 22 MNCs are sponsoring interventional trials in China, 18 have trial sites in Wuhan, the epicenter of the
#2019nCoV outbreak. An analysis of cos most active in the region finds Roche could be most affected. via@BioCentury https://www.biocentury.com/article/304378 pic.twitter.com/UhUM5dh5VE
-
$GILD to begin enrolling patients mid-Feb in 2 trials of#remdesivir to treat#2019nCoV acute respiratory disease via@BioCentury's@LaboratoryLiz https://www.biocentury.com/article/304364 pic.twitter.com/dLlAnArZS7
-
Delays hit clinical trials in China.
@BioCentury's@li_hongjiang speaks with Foundation's Dan Zhang and HitGen's Jin Li on#2019nCoV's impact on clinical research. https://www.biocentury.com/article/304370 For open access to all of BioCentury's#Coronavirus coverage see: https://www.biocentury.com/coronavirus pic.twitter.com/gDHRLigbA9
-
Top R&D execs out at AveXis: https://www.biocentury.com/bc-extra/company-news/2019-08-14/top-rd-execs-out-avexis … icymi here's
@BioCentury's timeline of the chain of events in the Zolgensma affair & story by@EMcCallister01 https://www.biocentury.com/biocentury/regulation/2019-08-09/how-zolgensma-debacle-unfolded-and-signs-novartis-might-have-missed …pic.twitter.com/ZIeDAV6ZDZ
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.